Conclusion bipolar disorders essay

Lurasidone treatment significantly reduced mean MADRS total scores at week 6 for both the 20-60 mg/day group (-; effect size=) and the 80-120 mg/day group (-; effect size=) compared with placebo (-). Similarly, lurasidone treatment resulted in significantly greater endpoint reduction in CGI-BP depression severity scores for both the 20-60 mg/day group (-; effect size=) and the 80-120 mg/day group (-; effect size=) compared with placebo (-). Both lurasidone groups also experienced significant improvements compared with placebo in anxiety symptoms and in patient-reported measures of quality of life and functional impairment. Discontinuation rates due to adverse events were similar in the 20-60 mg/day (%), 80-120 mg/day (%), and placebo (%) groups. The most frequent adverse events associated with lurasidone were nausea, headache, akathisia, and somnolence. Minimal changes in weight, lipids, and measures of glycemic control were observed with lurasidone.

Conclusion bipolar disorders essay

conclusion bipolar disorders essay

Media:

conclusion bipolar disorders essayconclusion bipolar disorders essayconclusion bipolar disorders essayconclusion bipolar disorders essay